SAN FRANCISCO, CA, Osmind today announced a $40 million Series B investment round.
Osmind, the public benefit corporation helping clinicians and researchers advance new life-saving mental health treatments, today announced a $40 million Series B investment led by DFJ Growth. The Series B round brings the total amount of funding for Osmind to $57 million since the company's founding in 2020. Justin Kao, partner at DFJ Growth, and the co-founder of Helix, will join the Osmind Board of Directors.
In addition to DFJ Growth, the round includes new investors Susa Ventures, Lachy Groom, Brent Saunders (former CEO and chairman of Allergan and current Osmind board member), Helena Goodman and Ariel Katz (CEO of H1 Insights), and existing investors General Catalyst, Future Ventures, Tiger Global, and Pear VC.
Osmind is a public benefit corporation led by scientists, technologists, and psychiatrists to advance new evidence-generating medicine that helps people living with moderate to severe mental health conditions.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about